At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Oral DS107 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Oral DS107 and Placebo for Atopic Dermatitis. Completed, enrolled 102 participants across 14 sites in 2 countries.
Detailed Summary
This study will compare the safety and efficacy of Oral DS107 (2 g) to placebo in patients with moderate to severe atopic dermatitis. Oral DS107 (2 g) will be orally administered for 8 weeks, and will be compared against placebo. This study will enroll approximately 100 adult patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartJan 2015
Primary CompletionNov 2015
Study CompletionDec 2015
TodayJul 2026
First PostedAug 7, 2014
Enrollment StartJan 1, 2015
Primary CompletionNov 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.9 years ago
Interventions
Oral DS107drug
Placebodrug